Phase III Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
A randomised, open-label, multicenter phase III study to evaluate the efficacy and safety of tucidinostat in combination with sintilimab and bevacizumab versus fruquintinib monotherapy in MSS/pMMR colorectal cancer patients.
Epistemonikos ID: a231d2100cc195a5ed4196ec793f4074bdf7e959
First added on: Aug 01, 2024